1 December 2009, 7:55 am
LONDON, UK—-1st December 2009—-New Publications. Two new research products have been now published by strategic research consultancy VacZine Analytics. The first, DiseaseINFOPACK: Clostridium difficile in China continues the longstanding company interest in C.diff and takes the first step to understanding the pathogen in large emerging economies.
The second new product, MarketVIEW: meningitis ACWY vaccines models the US market for pending product launches MenHibrix (GSK), Menveo (Novartis), and Menactra (Sanofi Pasteur). The product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all products within all age group indications in the critical US market for the next 10-15 years. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing recommendation/competitive and pricing scenarios. VISIT SITE TO LEARN MORE.
28 November 2009, 4:13 am
LONDON, UK—-20th November 2009—-ExpertREACT. At the recent Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009), new vaccines to protect against N.meningitidis (B) were discussed. Both Wyeth and Novartis Vaccines are positioning their approaches on the best science. VacZine Analytics discuss the current issues. READ ARTICLE.
13 November 2009, 4:41 am
LONDON, UK—-November 13th 2009—-VaccineSTATS. DATABASE update: Studies added to the most recent database update include the Staphylococcus Aureus Toxoids Vaccine Trial (Phase I/II) being conducted by the Uniformed Services University of the Health Sciences in collaboration with Nabi Biopharmaceuticals and the Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1 (Phase I) being conducted by PaxVax Inc. VISIT DATABASE.
10 November 2009, 4:41 am
LONDON, UK—-November 10th 2009—-VaccineSTATS. DATABASE update: Database registrants can now gain access to a new autogenerating chart feature which gives a dynamic snapshot of the fast moving vaccine R&D pipeline. The chart captures the whole vaccine R&D pipeline by development Phase and indicating the majority of vaccine clinical programs are in Phase I. VISIT DATABASE
3 November 2009, 6:45 am
LONDON, UK—-November 3rd 2009—-VaccineSTATS. DATABASE update: According to clinicaltrials.gov around 40 studies focused on influenza were logged between August 2009 and November 2009, the majority focused on H1N1 vaccines. Most studies were either Phase II and/or Phase III advancements. Interesting other inclusions were Sanofi Pasteur’s Quadrivalent seasonal candidate (QIV), UMN Pharma’s recombinant H5N1 candidate, UMN-0501 (Protein Sciences) being studied in Japan and Vaxinnate’s (VAX125) hemagglutinin (HA)-flagellin flu candidate now entering Phase II. VISIT DATABASE
1 November 2009, 5:52 am
LONDON, UK—-November 1st 2009—-VaccineSTATS. DATABASE update: Studies added to the most recent database update include the Sanaria Inc new malaria vaccine (PfSPZ, in partnership with PATH MVI), a new Phase I/II challenge study for Ligocyte’s norovirus (Norwalk) vaccine, Xcellerex Inc (yellow fever) and Merck & Co’s Phase I study in China for Rotateq (V260). VISIT DATABASE.
28 October 2009, 11:59 am
LONDON, UK—-October 28th 2009—-VaccineSTATS. DATABASE update: As part of their Q3 2009 results presentation GSK confirmed US filing in August of their Hib-MenC/Y (GSK792014) vaccine known as Menhibrix. The vaccine brings competition to Novartis Vaccines (Menveo) and Sanofi Pasteur (Menactra) also aiming for meningitis protection in the infants <2 yrs group. VISIT DATABASE.
24 October 2009, 12:02 pm
LONDON, UK—-October 24th 2009—-VaccineSTATS. VacZine Analytics, as part of its VaccineSTATS product range has now launched Vaccine Pipeline Review (September 2009) to a fully interactive on-line version. Registered clients can now monitor the fast moving research and development pipeline with either a free “standard” database or a pay for “premium” database with added features and functionality. Register at: Click here>>
24 October 2009, 11:31 am
LONDON, UK—-20th October 2009—-ExpertREACT. The FDA’s decision to approve GSK Biological’s Cervarix® is not only a step forward for human papilloma virus (HPV) disease prevention; it is a step forward for the whole vaccine industry. With FDA policy towards new adjuvants now evolving, VacZine Analytics believes the industry will now elevate investment in the field. Once again the H1N1 pandemic is a catalyst. READ FULL ARTICLE…
Rethinking new meningitis ACWY vaccines
LONDON, UK—-17th November 2009—-ExpertREACT. At the recent Meningitis Research Foundation (MRF) meeting in London (12th & 13th November 2009), new vaccines to protect against N.meningitidis (ACWY) were discussed. Question marks around inclusion on the US infant schedule will force manufacturers to consider other penetration strategies. VacZine Analytics discusses the current issues. READ ARTICLE.